April 20, 2021
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory scienceSIGN UP ⋅   SHARE
Europe
A review has been initiated by the European Medicines Agency for VIR-7831, the investigational monoclonal antibody co-developed by GlaxoSmithKline and Vir Biotechnology as an early treatment for COVID-19. Included in the review will be an interim analysis of safety and efficacy data for 583 randomized patients, which showed the treatment reduced hospitalization or mortality by 85% in participants who received the monoclonal antibody in comparison to those given a placebo.
Full Story: PharmaTimes online (UK) (4/16) 
LinkedIn Twitter Facebook Email
The European Commission reportedly will not renew its COVID-19 vaccine contracts with AstraZeneca and Johnson & Johnson when they expire at the end of the year over concerns about blood clots and delivery disruptions, according to an Italian health official quoted in La Stampa. However, a European Commission spokesperson said the bloc is keeping all options open.
Full Story: FiercePharma (4/14) 
LinkedIn Twitter Facebook Email
Asia Pacific
Chinese health regulators are reportedly considering approval of the Pfizer/BioNTech COVID-19 vaccine this summer, which would be the first Western vaccine approved by the country. About 100 million doses are expected to be delivered to China by the end of the year through a deal with BioNTech and Shanghai Fosun Pharmaceutical Group Co.
Full Story: The Wall Street Journal (4/16),  Reuters (4/16) 
LinkedIn Twitter Facebook Email
India is delaying its contributions to the global vaccine-sharing initiative COVAX as an outbreak in COVID-19 cases is leading to shortages in some Indian states. India is the world's largest vaccine producer and was providing doses of the AstraZeneca/Oxford vaccine manufactured by the Serum Institute of India.
Full Story: CNN (4/18) 
LinkedIn Twitter Facebook Email
Diversity & Inclusion in Rare Disease Trials
Patient enrollment is challenging for rare disease clinical trials. Enrollment success requires more inclusive study design and technology-driven solutions. Learn how patient advocacy groups as critical stakeholders lead to more diverse patient populations: Download whitepaper.
ADVERTISEMENT:
North America
Mayne Pharma has gained the FDA's approval for its contraceptive Nextstellis, or drospirenone and estetrol, which is expected to become commercially available by the end of June.
Full Story: eMPR (4/16) 
LinkedIn Twitter Facebook Email
The FDA has revoked the emergency use authorization granted to Eli Lilly and Co.'s monoclonal antibody drug bamlanivimab as a standalone therapy against COVID-19 due to the emergence of variants resistant to the drug, just hours after Eli Lilly made the request. The agency said the benefits of using bamlanivimab alone "no longer outweigh the known and potential risks for its authorized use."
Full Story: The Hill (4/16) 
LinkedIn Twitter Facebook Email
The Centers for Disease Control and Prevention could decide by Friday if restrictions will be added to the Johnson & Johnson vaccine after six women reported blood clotting issues after receiving the shot, according to Dr. Anthony Fauci. The US paused use of J&J's vaccines last week.
Full Story: KOMO-TV/KOMO-AM (Seattle) (4/19) 
LinkedIn Twitter Facebook Email
Global
Wealthy countries must donate excess doses of COVID-19 vaccines to the World Health Organization's COVAX initiative for distribution in less developed countries, officials urged this week, noting many poor countries had yet to receive a single dose of the vaccines. Europe this week surpassed one million coronavirus-related deaths, and WHO Director-General Dr. Tedros Adhanom Ghebreyesus warns new cases are nearing the highest level seen since the pandemic began.
Full Story: CNBC (4/16),  Reuters (4/15),  The Associated Press (4/15) 
LinkedIn Twitter Facebook Email
DIA News
What life sciences developments will be talked about this year? Who will you meet? There's no telling -- well, maybe there is -- with the official release of the DIA 2021 Global Annual Meeting Program!

That's right, the DIA 2021 Program is now available and searchable! Review this year's hottest topics, our 200+ live and on-demand sessions over 13 educational tracks, various learning formats, and more. You can also filter by track or date, and change the time zone to your own so you'll never miss a thing! Follow one track, combine formats, pop in and out of sessions, or plan to watch on your time -- the opportunities are endless! Advance rates expire on April 15, so start planning your schedule today!
LinkedIn Twitter Facebook Email
Further your career and advance your current skillset with DIA virtual events this year. DIA events help professionals to stay on top of policy changes, best practices, and updated guidances through interactive workshops, engaging sessions, and networking event -- now held on your device anywhere in the world. Check out our upcoming, can't-miss conferences and trainings for healthcare and life sciences professionals to take yourself to the next level: 
LinkedIn Twitter Facebook Email
LEARN MORE ABOUT DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
Sharing DIA Global SmartBrief with your network keeps the quality of content high and these newsletters free.
Help Spread the Word
SHARE
Or copy and share your personalized link:
smartbrief.com/dia/?referrerId=eSriBJbAIQ
It is so easy to exist instead of live. Unless you know there is a clock ticking.
Anna Quindlen,
writer, journalist, columnist
LinkedIn Twitter Facebook Email
 
SmartBrief publishes more than 200 free industry newsletters - Browse our portfolio
Sign Up  |    Update Profile  |    Advertise with SmartBrief
Unsubscribe  |    Privacy policy
CONTACT US: FEEDBACK  |    ADVERTISE
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004